HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Resveratrol Partners Asks For IND Waiver On Macular Degeneration Claim

This article was originally published in The Tan Sheet

Executive Summary

Resveratrol Partners submitted a petition that argues FDA regulations slow the development of health care products to address public health needs, such as the treatment of wet age-related macular degeneration. “It’s the public’s welfare, it’s not about rules and regulations,” says the firm’s managing partner, Bill Sardi.

You may also be interested in...



Glaxo Shifts Rx Resveratrol Focus But Nutritional Interest Still Strong

GlaxoSmithKline's decision to abandon its pharmaceutical research program on resveratrol leaves the red wine extract exclusively to the nutritionals industry.

FDA Guidance Raises Prospect Of More INDs For Supplement Research

An FDA draft guidance that seeks to clarify when an investigational new drug application should be filed may add logistical knots to the process of studying foods and dietary ingredients, stakeholders say.

Monetary Relief Slim From Dietary Supplement Multi-level Marketer Operating Pyramid Scheme

Federal judge found for FTC on all counts in its complaint against defendants linked to MLM selling Success By Health supplements through affiliates, or independent sales associates. But damages limited to $6,829 for five instances of rejecting consumer requests for refunds after shipping delay.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124893

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel